Arhalofenate
- Generic Name
- Arhalofenate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17ClF3NO4
- CAS Number
- 24136-23-0
- Unique Ingredient Identifier
- 1P01UJR9X1
- Background
Arhalofenate has been investigated for the treatment of Gout and Hyperuricemia.
- Associated Conditions
- -
- Associated Therapies
- -
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02252835
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01416402
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-21
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01399008
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01336686
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath